{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-009060","form_type":"8-K","ticker":"ETON","cik":"0001710340","company_name":"Eton Pharmaceuticals, Inc.","filed_at":"2026-03-19T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.967419+00:00","generated_at":"2026-05-15T09:38:56.437416+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Eton Pharma Q4 product sales $21.3M (+83% YoY); guides FY26 rev >$110M, 30%+ EBITDA margin","bullets":["Q4 product sales $21.3M (+83% YoY); GAAP diluted EPS $0.05, non-GAAP diluted EPS $0.19; Adj. EBITDA $6.2M","Launched DESMODA (first FDA-approved desmopressin oral solution) on March 9, 2026","Acquired U.S. rights to Orphan Drug HEMANGEOL; relaunch May 1, 2026; accretive to 2026 earnings","FY 2026 guidance: revenue >$110M, Adj. EBITDA margin >30%","Cash $25.9M at Dec 31, 2025; net income $1.5M vs loss $5.4M prior year"],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-009060","json":"https://secwatch.observer/filing/0001437749-26-009060.json","markdown":"https://secwatch.observer/filing/0001437749-26-009060.md","text":"https://secwatch.observer/filing/0001437749-26-009060.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1710340/000143774926009060/0001437749-26-009060-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1710340/000143774926009060/eton20251117_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T09:38:56.437416+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}